Maarit K Leinonen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6047449/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prenatal exposure to nitrofurantoin and risk of childhood leukaemia: a registry-based cohort study in four Nordic countries. International Journal of Epidemiology, 2022, 51, 778-788.	1.9	3
2	Antipsychotic use in pregnancy and risk of attention/deficit-hyperactivity disorder and autism spectrum disorder: a Nordic cohort study. Evidence-Based Mental Health, 2022, 25, 54-62.	4.5	13
3	Folic Acid and Risk of Preterm Birth, Preeclampsia, and Fetal Growth Restriction Among Women With Epilepsy. Neurology, 2022, 99, .	1.1	12
4	Extended spectrum penicillins reduce the risk of omphalocele: A population-based case-control study. Journal of Pediatric Surgery, 2021, 56, 1590-1595.	1.6	4
5	Preterm birth, neonatal therapies and the risk of childhood cancer. International Journal of Cancer, 2021, 148, 2139-2147.	5.1	12
6	Maternal autoimmune disease is not associated with cancer in the offspring. Acta Paediatrica, International Journal of Paediatrics, 2021, 110, 2259-2266.	1.5	4
7	Maternal Medication Use and Childhood Cancer in Offspring—Systematic Review and Considerations for Researchers. American Journal of Epidemiology, 2021, 190, 2487-2499.	3.4	2
8	Prune belly syndrome in Finland – A population-based study on current epidemiology and hospital admissions. Journal of Pediatric Urology, 2021, 17, 702.e1-702.e6.	1.1	3
9	Second-generation antipsychotic use during pregnancy and risk of congenital malformations. European Journal of Clinical Pharmacology, 2021, 77, 1737-1745.	1.9	16
10	Maternal Thyroid Disease and the Risk of Childhood Cancer in the Offspring. Cancers, 2021, 13, 5409.	3.7	3
11	Maternal diabetes and risk of childhood cancer in the offspring. International Journal of Cancer, 2020, 147, 662-668.	5.1	12
12	Second-generation antipsychotics and pregnancy complications. European Journal of Clinical Pharmacology, 2020, 76, 107-115.	1.9	22
13	Placental transporterâ€mediated drug interactions and offspring congenital anomalies. British Journal of Clinical Pharmacology, 2020, 86, 868-879.	2.4	9
14	Maternal hyperthyroidism and pregnancy outcomes: A populationâ€based cohort study. Clinical Endocrinology, 2020, 93, 721-728.	2.4	26
15	Paediatric infections in the first 3 years of life after maternal antiâ€TNF treatment during pregnancy. Alimentary Pharmacology and Therapeutics, 2020, 52, 843-854.	3.7	25
16	Maternal risk factors for gastroschisis: A populationâ€based case–control study. Birth Defects Research, 2020, 112, 989-995.	1.5	16
17	Prevalence trends and individual patterns of antiepileptic drug use in pregnancy 2006â€2016: A study in the five Nordic countries, United States, and Australia. Pharmacoepidemiology and Drug Safety, 2020, 29, 913-922.	1.9	23
18	Prevalence of positive screening test results and agreement between cytology and human papillomavirus testing in primary cervical cancer screening in North-Western Romania. European Journal of Cancer Prevention, 2020, 29, 141-148.	1.3	3

Maarit K Leinonen

#	Article	IF	CITATIONS
19	Antipsychotic drug use in pregnancy: A multinational study from ten countries. Schizophrenia Research, 2020, 220, 106-115.	2.0	30
20	Completeness of pediatric cancer registration in the Finnish Cancer Registry. Acta Oncológica, 2019, 58, 1577-1580.	1.8	15
21	The European study on centralisation of childhood cancer treatment. European Journal of Cancer, 2019, 115, 120-127.	2.8	12
22	Recent increase in incidence of cervical precancerous lesions in Norway: Nationwide study from 1992 to 2016. International Journal of Cancer, 2019, 145, 2629-2638.	5.1	27
23	Antidiabetic medication use during pregnancy: an international utilization study. BMJ Open Diabetes Research and Care, 2019, 7, e000759.	2.8	35
24	Treatment challenges in and outside a network setting: Soft tissue sarcomas. European Journal of Surgical Oncology, 2019, 45, 31-39.	1.0	27
25	Epidemiology of rare cancers and inequalities in oncologic outcomes. European Journal of Surgical Oncology, 2019, 45, 3-11.	1.0	47
26	Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours. European Journal of Surgical Oncology, 2019, 45, 46-51.	1.0	3
27	Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting. European Journal of Surgical Oncology, 2019, 45, 67-74.	1.0	22
28	Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting. European Journal of Surgical Oncology, 2019, 45, 75-80.	1.0	15
29	Testicular germ-cell tumours and penile squamous cell carcinoma: Appropriate management makes the difference. European Journal of Surgical Oncology, 2019, 45, 60-66.	1.0	4
30	Treatment challenges in and outside a network setting: Head and neck cancers. European Journal of Surgical Oncology, 2019, 45, 40-45.	1.0	27
31	Safety and acceptability of human papillomavirus testing of self-collected specimens: A methodologic study of the impact of collection devices and HPV assays on sensitivity for cervical cancer and high-grade lesions. Journal of Clinical Virology, 2018, 99-100, 22-30.	3.1	32
32	Low proportion of unreported cervical treatments in the cancer registry of Norway between 1998 and 2013. Acta Oncológica, 2018, 57, 1663-1670.	1.8	8
33	Quality measures of the population-based Finnish Cancer Registry indicate sound data quality for solid malignant tumours. European Journal of Cancer, 2017, 77, 31-39.	2.8	159
34	Personal and provider level factors influence participation to cervical cancer screening: A retrospective register-based study of 1.3 million women in Norway. Preventive Medicine, 2017, 94, 31-39.	3.4	46
35	Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study. Lancet Oncology, The, 2017, 18, 1022-1039.	10.7	285
36	Barriers to cervical cancer screening faced by immigrants: a registry-based study of 1.4 million women in Norway. European Journal of Public Health, 2017, 27, 873-879.	0.3	52

Maarit K Leinonen

#	Article	IF	CITATIONS
37	Reproductive history and risk of colorectal adenocarcinoma in parous women: a Nordic population-based case–control study. British Journal of Cancer, 2016, 115, 1416-1420.	6.4	5
38	Coverage and accuracy of myeloproliferative and myelodysplastic neoplasms in the Finnish Cancer Registry. Acta Oncológica, 2016, 55, 782-786.	1.8	11
39	Type- and age-specific distribution of human papillomavirus in women attending cervical cancer screening in Finland. British Journal of Cancer, 2013, 109, 2941-2950.	6.4	29
40	The HPV test has similar sensitivity but more overdiagnosis than the Pap test—A randomised health services study on cervical cancer screening in Finland. International Journal of Cancer, 2013, 132, 2141-2147.	5.1	61
41	Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland. BMJ, The, 2012, 345, e7789-e7789.	6.0	80
42	Validation of histological diagnoses in a national cervical screening register. Acta Oncológica, 2012, 51, 37-44.	1.8	9
43	Response: Re: Age-Specific Evaluation of Primary Human Papillomavirus Screening vs Conventional Cytology in a Randomized Setting. Journal of the National Cancer Institute, 2010, 102, 739-740.	6.3	Ο
44	Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. BMJ: British Medical Journal, 2010, 340, c1804-c1804.	2.3	143
45	Age-Specific Evaluation of Primary Human Papillomavirus Screening vs Conventional Cytology in a Randomized Setting. Journal of the National Cancer Institute, 2009, 101, 1612-1623.	6.3	224
46	Prevalence of oncogenic human papillomavirus infection in an organised screening population in Finland. International Journal of Cancer, 2008, 123, 1344-1349.	5.1	26
47	Fecundity and morbidity following acute pelvic inflammatory disease treated with doxycycline and metronidazole. Archives of Gynecology and Obstetrics, 2003, 268, 284-288.	1.7	27
48	Indications for intensive care unit treatment among neonates born to mothers with thyroid disease: A populationâ€based cohort study. Acta Obstetricia Et Gynecologica Scandinavica, 0, , .	2.8	2